Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

April 30, 2009

Conditions
Breast Cancer
Interventions
DRUG

Doxorubicin

doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)

DRUG

Cyclophosphamide

Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)

DRUG

Docetaxel

Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)

Trial Locations (24)

Unknown

Jeroen Bosch Ziekenhuis, 's-Hertogenbosch

Onze Lieve Vrouwe Gasthuis, Amsterdam

Rijnstate Ziekenhuis, Arnhem

Deventer Ziekenhuis, Deventer

Slingeland Hospital, Doetinchem

Catharina Ziekenhuis, Eindhoven

St. Anna Hospital, Geldrop

St. Jansdal Ziekenhuis, Harderwijk

Atrium Medisch Centrum, Heerlen

Elkerliek Ziekenhuis, Helmond

Spaarne Ziekenhuis, Hoofddorp

Leids Universitair Medisch Centrum (LUMC), Leiden

Academical Hospital Maastricht (AZM), Maastricht

St. Antonius Hospital, Nieuwegein

Canisius Wilhelmina Ziekenhuis, Nijmegen

Radboud University Medical Centre, Nijmegen

Waterland Hospital, Purmerend

Maasland Hospital, Sittard

HAGA Ziekenhuis, The Hague

St. Elisabeth Ziekenhuis, Tilburg

Mesos Medisch Centrum, Utrecht

UMC Utrecht, Utrecht

Maxima Medisch Centrum, Veldhoven

Zaans Medical Centre, Zaandam

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT00314977 - Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer. | Biotech Hunter | Biotech Hunter